Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review.

ABSTRACT:

Background

Evaluation of health-related quality of life (HR-QoL) among cancer patients has gained an increasing importance and is now a key determinant of anticancer treatments' value. HR-QoL has been assessed in trials testing cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in breast cancer (BC), using various questionnaires at different timepoints. HR-QoL reports from BC patients treated with CDK4/6i in the real-world setting are also available.

Methods

We systematically reviewed the literature, searching for full-length articles, and selected conference abstracts reporting data on HR-QoL in BC patients at any stage and of any molecular subtype treated with abemaciclib, palbociclib or ribociclib.

Results

A total of 533 full-length articles and 143 abstracts were re

SUBMITTER: Di Lauro V 

PROVIDER: S-EPMC9808450 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature